Humbert M, et al. - Researchers analyzed data from two Phase 3 studies (MENSA [MEA115588/NCT01691521]; MUSCA [200862/NCT02281318]) in this post hoc meta-analysis, to assess the effectiveness of the licensed dose of mepolizumab (100 mg given subcutaneously [SC]) vs placebo in patients with severe eosinophilic asthma (SEA), according to omalizumab eligibility and related allergic features. Placebo, mepolizumab 100 mg SC or 75 mg intravenously, plus standard of care (high-dose inhaled corticosteroids and other controllers) was administered every 4 weeks to patients ≥12 years of age with SEA who had ≥2 exacerbations in the previous year. This analysis included data from patients who received ≥1 dose placebo or mepolizumab 100 mg SC. According to the findings, mepolizumab 100 mg SC is clinically beneficial in patients with blood eosinophil counts ≥150 cells/μL (or history of ≥300 cells/μL), irrespective of allergic features or omalizumab eligibility.